Compare Regeneron Pharmaceuticals Inc (REGN) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while ZIM Integrated Shipping Services Ltd trades at $25.02 (market cap $3.00B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 23.6× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals.
| REGN | ZIM | |
|---|---|---|
Market Cap | $70.79B | $3.00B |
Sector | Health | Industrials |
52-Week High | $812.27 | $29.27 |
52-Week Low | $545.46 | $12.44 |
Enterprise Value | $64.74B | $6.85B |
Dividend Yield | 0.56% | 20.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
ZIM trades at $24.31, showing minimal daily movement. The stock faces a bearish technical outlook with mixed earnings, including a Q1 2026 miss. Financially, it maintains a strong cash position and low valuation multiples, but profitability has declined from 2025 to 2026. Recent news is dominated by merger uncertainty with Hapag-Lloyd and leadership changes.
The outlook is cautious due to regulatory risks around the merger and volatile shipping rates. Upside exists if the deal proceeds or freight markets tighten, but downside risk is significant if the merger fails, with analyst targets near $16.75. High cash burn and insider selling add to near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
